A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function

Author(s):
Sharma, S.; Witteveen, P.O.; Lolkema, M.P.; Hess, D.; Gelderblom, H.; Hussain, S.A.; Porro, M.G.; Waldron, E.; Valera, S.Z.; Mu, S.
Published
2015
Publication type
Article / Letter to editor
Renal impairmentPanobinostatPan-deacetylase inhibitorHistonePhase I
Date issued
2015-01-31
Language
English
Is part of
Cancer Chemotherapy and Pharmacology (2015), Vol. 75, no. 1, p. 87-95
hdl
1887/107995
doi
10.1007/s00280-014-2612-8